Brokerages forecast that Ceridian HCM Holding Inc (NYSE:CDAY) will report $220.48 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Ceridian HCM’s earnings, with the lowest sales estimate coming in at $216.80 million and the highest estimate coming in at $221.61 million. Ceridian HCM posted sales of $200.30 million in the same quarter last year, which indicates a positive year over year growth rate of 10.1%. The company is expected to announce its next quarterly earnings results on Wednesday, February 5th.

On average, analysts expect that Ceridian HCM will report full-year sales of $822.78 million for the current fiscal year, with estimates ranging from $819.10 million to $823.91 million. For the next fiscal year, analysts anticipate that the firm will report sales of $927.68 million, with estimates ranging from $922.00 million to $938.70 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover Ceridian HCM.

Ceridian HCM (NYSE:CDAY) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.07 by $0.04. The business had revenue of $202.30 million during the quarter, compared to analyst estimates of $196.52 million. Ceridian HCM had a return on equity of 2.24% and a net margin of 11.34%. The firm’s revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.10 EPS.

Several equities research analysts have recently issued reports on the company. TheStreet upgraded Ceridian HCM from a “d+” rating to a “c-” rating in a report on Wednesday, November 20th. Mizuho set a $65.00 price target on Ceridian HCM and gave the company a “buy” rating in a report on Friday, September 6th. Cantor Fitzgerald assumed coverage on Ceridian HCM in a report on Wednesday, September 11th. They set an “overweight” rating and a $65.00 price target for the company. ValuEngine lowered Ceridian HCM from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. Finally, Barclays set a $52.00 price target on Ceridian HCM and gave the company a “hold” rating in a report on Friday, November 1st. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $57.15.

Shares of Ceridian HCM stock traded up $0.01 during trading on Wednesday, hitting $60.37. 1,067,000 shares of the stock traded hands, compared to its average volume of 973,106. The stock has a market cap of $8.69 billion, a P/E ratio of -1,207.40 and a beta of 1.57. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.10 and a current ratio of 1.10. Ceridian HCM has a twelve month low of $31.39 and a twelve month high of $61.15. The company has a fifty day moving average price of $52.25 and a two-hundred day moving average price of $51.64.

In related news, CEO David D. Ossip sold 500,000 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $56.00, for a total value of $28,000,000.00. Also, Director Cannae Holdings, Inc. sold 5,000,000 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $53.08, for a total value of $265,400,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 12,006,250 shares of company stock valued at $657,725,063. Corporate insiders own 26.90% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Metropolitan Life Insurance Co NY increased its position in Ceridian HCM by 25.2% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 5,213 shares of the company’s stock worth $257,000 after buying an additional 1,049 shares during the period. Select Equity Group L.P. increased its position in Ceridian HCM by 32.4% in the 3rd quarter. Select Equity Group L.P. now owns 8,434,199 shares of the company’s stock worth $416,396,000 after buying an additional 2,064,472 shares during the period. Squarepoint Ops LLC bought a new position in Ceridian HCM in the 3rd quarter worth approximately $888,000. Tyrus Capital S.A.M. bought a new position in Ceridian HCM in the 3rd quarter worth approximately $1,145,000. Finally, York Capital Management Global Advisors LLC bought a new position in Ceridian HCM in the 3rd quarter worth approximately $4,279,000. Hedge funds and other institutional investors own 82.99% of the company’s stock.

About Ceridian HCM

Ceridian HCM Holding Inc operates as a human capital management (HCM) software company in the United States and internationally. The company offers Dayforce, a cloud HCM platform that provides human resources (HR), payroll, benefits, workforce management, and talent management functionality; and Powerpay, a cloud platform, which offers scalable and straightforward payroll and HR solutions.

See Also: Back-End Load

Get a free copy of the Zacks research report on Ceridian HCM (CDAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ceridian HCM (NYSE:CDAY)

Receive News & Ratings for Ceridian HCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ceridian HCM and related companies with MarketBeat.com's FREE daily email newsletter.